SWSarah Wise

Sarah Wise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Wise has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Socioeconomic dispersion of publicly funded intravenous iron therapies for iron deficiency during pregnancy in Australia: a retrospective population-based cohort study

    by Hannah Jackson, Luke Grzeskowiak, Joanne Enticott, Sarah Wise, Emily Callander

    Objectives: Iron deficiency in pregnancy poses significant risks to maternal and fetal health, which are exacerbated by socioeconomic disadvantage. The objective of this study was to assess the socioeconomic distribution of publicly funded intravenous iron therapies for iron deficiency in pregnant women, evaluating the capacity of public policy to promote equal access to medications. Study type: Retrospective, population-based cohort study. Methods: The Maternity1000 dataset was used to analyse access to and public expenditure on intravenous iron therapies dispensed via the Pharmaceutical Benefits Scheme (PBS) during 176,036 pregnancies (July 2015 to June 2018) in Queensland, Australia; stratified by socioeconomic status. Inequalities were assessed through benefit incidence analyses and concentration indices (C). Results: Diagnosed iron deficiency was more common among women living in less disadvantaged areas (Q5: 7.58% vs Q1: 5.06%). Access to ferric carboxymaltose showed no significant socioeconomic-related inequality overall (Coverall = 0.004; P = 0.594). However, annual concentration indices increased incrementally over the study timeframe, with a small shift in the distribution of access towards women living in less disadvantaged areas in 2017/18 (C2017/18 = 0.038; P < 0.001). In contrast, access to iron polymaltose showed no evidence of socioeconomic inequality (Coverall = −0.024; P = 0.358). Government expenditure on iron polymaltose was consistently concentrated among more disadvantaged areas; reflecting its lower cost and reduced government contribution for less disadvantaged women. Government expenditure on ferric carboxymaltose was evenly distributed overall (Coverall = −0.011; P = 0.130), with annual stratification showing public expenditure became increasingly concentrated among less disadvantaged areas in 2017/18 (C2017/18 = 0.027; P = 0.011). Conclusions: The PBS plays an important role in supporting intravenous iron access in pregnancy, although minor socioeconomic disparities may be emerging for newer, higher-cost formulations. Ongoing monitoring is needed to ensure rising public expenditure delivers equitable, high-value maternal care without deepening existing inequalities.

  • Open Access

    Questioning the cost of convenience: a mixed methods study of the impact of a telehealth service delivery on pharmacists’ work

    by Jane E. Carland, Christine T. Shiner, Vishal Suresh, Terry Melocco, Michelle Le, Sarah Wise

    Telehealth represents a fundamental change to the health care delivery process. Despite the burgeoning literature on the rapid expansion of telehealth serv

  • Open Access

    Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme

    by Hannah Jackson, Luke Grzeskowiak, Joanne Enticott, Sarah Wise, Emily Callander

    Introduction: Nausea and vomiting in pregnancy is highly prevalent and can significantly impact pregnant women's quality of life. Despite this, access to effective pharmacotherapies can be constrained by stringent regulatory controls and socioeconomic barriers. The objective of this study was to examine the socioeconomic distribution of antiemetics (metoclopramide, ondansetron, and prochlorperazine) dispensed to pregnant women through Australia's publicly subsidized Pharmaceutical Benefits Scheme. Material and Methods: We used the Maternity1000 linked administrative dataset to characterize antiemetics dispensed during 297 630 pregnancies in Queensland, Australia (July 2013 to June 2018). Using a population‐based historical cohort study design, we analyzed dispensing volume, prevalence, and government expenditure across socioeconomic quintiles, with socioeconomic disadvantage defined using the Australian Bureau of Statistics' Index of Relative Socioeconomic Disadvantage. Inequalities in medication access and public expenditure were assessed using concentration indices (C) and concentration curves. Results: Off‐label ondansetron dispensings for nausea and vomiting in pregnancy (i.e., use outside Therapeutic Goods Administration‐approved indications and not subsidized under the Pharmaceutical Benefits Scheme) accounted for the largest share of public expenditure (53.5%), followed by metoclopramide (45.2%) and prochlorperazine (1.3%). Across all three antiemetics, prevalence was highest among women in the most socioeconomically disadvantaged quintiles and declined progressively across the two least disadvantaged groups. Small pro‐poor inequalities in access (C < −0.10) and moderate pro‐poor inequalities in public expenditure (C > −0.25) were observed across all antiemetics. (Medication access: C metoclopramide = −0.07, 95% CI (−0.080 to −0.068); C ondansetron = −0.09, 95% CI (−0.114 to −0.075); C prochlorperazine = −0.08, 95% CI (−0.109 to −0.045). Government expenditure: C metoclopramide = −0.30, 95% CI (−0.316 to −0.285); C ondansetron = −0.25, 95% CI (−0.297 to −0.198); C prochlorperazine = −0.28, 95% CI (−0.350 to −0.205)). Conclusions: Off‐label ondansetron access accounted for the majority of public expenditure on antiemetics dispensed during pregnancy, revealing a disconnect between health policy, clinical practice, public expenditure, and pregnant women's needs. While pro‐poor access and public subsidies for antiemetics align with the equity elements embedded in the design of the Pharmaceutical Benefits Scheme, they may also be reflective of inequitable access to other unsubsidized, guideline‐recommended pharmacotherapies for nausea and vomiting in pregnancy.

  • Open Access

    Assessing the role of Australia’s Pharmaceutical Benefits Scheme as a tool for addressing inequality in access to medications and allocation of public funds for pregnant women

    by Hannah Jackson, Luke Grzeskowiak, Joanne Enticott, Sarah Wise, Emily J Callander

    Introduction: Medication use during pregnancy is common, and socioeconomic disparities in access may contribute to maternal and fetal health inequalities. This study examines socioeconomic disparities in access to and expenditure on medications dispensed through Australia’s Pharmaceutical Benefits Scheme (PBS), evaluating its role in promoting equal access to medications for pregnant women. Methods: We analysed the Maternity1000 linked administrative dataset, which includes data on 57 443 women who gave birth in Queensland, Australia, between 1 July 2017 and 30 June 2018. Socioeconomic quintiles were assigned using the Index of Relative Socioeconomic Disadvantage. Medication prevalence rates, usage proportions and costs (2022/2023 Australian dollar) were calculated, followed by concentration curves and indices to assess inequality. Results: Medication prevalence was higher among more disadvantaged women (Q1 (most disadvantaged): 67% vs Q5 (least disadvantaged): 60%), who were also dispensed a higher average number of medications per pregnancy (Q1: 2.8 (95% CI 2.7 to 2.9) vs Q5: 2.4 (95% CI 2.3 to 2.5)). However, the total medication cost (patient contribution amount plus public subsidy) was, on average, lower for these women (Q1: $45 (95% CI 43 to 46) vs Q5: $52 (95% CI 50 to 54)), indicating potential disparities in access to newer, higher cost treatments. The unadjusted concentration index suggested mild pro-poor inequality in access (CI=−0.031; pNA =−0.007; p=0.089). Government expenditure on medications showed no significant socioeconomic inequality (unadjusted CI=0.001; p=0.965). Conclusion: The PBS facilitates equitable access to publicly funded medications for pregnant women. However, the uniform distribution of public funds across socioeconomic groups suggests possible limitations in progressivity, as public subsidies are not disproportionately benefiting the most disadvantaged women overall. This may reflect missed opportunities to distribute public funds more effectively and efficiently, particularly if disadvantaged women are under-represented in access to newer, higher cost therapies, and warrants ongoing evaluation.

  • Open Access

    Tele-triaging: a qualitative study exploring pharmacists’ clinical decision-making in a Poisons Information Centre using interviews and a clinical vignette

    by Qi Xuan Koh, Sarah Wise, Deborah Debono, Darren M. Roberts, Jane E. Carland

    Introduction: Specialists in Poisons Information (SPIs), most of whom are pharmacists, work in Australian Poisons Information Centres (PICs) and provide telephone-based triage (tele-triage) and management advice for poison exposures. Australian PICs answer calls from the public and healthcare practitioners and are considered an emergency telephone service. While tele-triaging and clinical decision-making have been explored in other health professions, limited studies are available exploring how pharmacists apply their knowledge to make clinical decisions in a busy tele-triage emergency setting. Aim: To explore how SPIs apply clinical judgement in tele-triage and to understand the factors that shape their decision-making. Method: This study represents the second, qualitative phase of an exploratory sequential mixed-methods design examining calls related to unintentional poisoning exposures in older adults (≥ 75 years) to the New South Wales PIC. Semi-structured interviews with 12 SPIs were conducted, supported by clinical vignettes and analysed using an inductive approach. Thematic analysis was combined with process mapping to describe the decision-making process. Results: SPIs followed a flexible, three-phase process of information gathering, risk stratification, and management decision-making. This process was iterative, shaped by experience, clinical knowledge, and the urgency of the call. Decision-making relied on the ability to balance known and uncertain risks, interpret caller information, and assess social and clinical context. While structured guidelines supported consistency, SPIs emphasised the importance of clinical autonomy, particularly in complex cases. A strong collegial culture and peer learning were central to developing decision-making skills. Time pressure and documentation requirements created tensions, highlighting the need to align workflows with clinical priorities. Conclusion: SPI decision-making is a dynamic, context-dependent process that combines clinical expertise, guideline use, and real-time judgement. Findings have implications for SPI training, documentation systems, and the design of telehealth services involving complex risk assessment.

  • Unintentional poisoning in older Australians: a retrospective audit of New South Wales Poisons Information Centre data

    by Qi Xuan Koh, Sarah Wise, Jacques E. Raubenheimer, Deborah Debono, Darren M. Roberts, Jane E. Carland

    Poisons information centres provide phone-based risk assessment and management advice on poisonings. Unintentional poisonings are a common reason for consulting a poisons information centre, and older adults are at increased risk of unintentional poisoning and adverse outcomes. We describe patterns of unintentional poisoning in older adults reported to a regional poisons information centre. We conducted a retrospective audit of poisons information centre call records and identified unintentional poisonings involving older adults (≥75 years) over a 12-month period to determine patient demographics and poisoning circumstances (substances, contributing factors, and disposition recommendation). Univariate analyses identified variables associated with hospital referral and multivariate models to identify independent risk factors in home-dwelling older adults. We identified 2,757 calls. More exposures occurred in women (62%) and involved therapeutic errors (70.8%). Paracetamol was the most common drug involved (11%), and cardiovascular drugs were the most common drug class (36%). Only 14.3% of the study population was referred to hospital. Independent risk factors for hospital referral in home-dwelling older adults were exposure to cardiovascular, centrally acting and antihyperglycaemics, non-oral route of administration and symptoms at the time of the call. Unintentional poisoning is not uncommon, and our findings are similar to those in other countries over recent decades. These findings suggest that unintentional poisoning in older adults is inadequately addressed by current medication safety strategies. Our findings indicate the value of timely advice by poisons information centres for preventing potentially unnecessary hospitalizations. Further research is needed to identify more effective approaches to medication safety strategies for older adults. Poisons information centre data contribute to pharmacovigilance activities and could inform patient care.


  • Open Access

    Designing and implementing a bundle of care for patients with early-stage breast cancer: lessons from a pilot program

    by Yvonne Zissiadis, Helen Ballal, Nicola Forsyth, Angela Ives, Lee Jackson, Anna Montgomery, Sarah Wise, Wen Chan Yeow, Christobel Saunders

    We present a case study on the design and implementation of a value-based bundled package of care for patients with early-stage breast cancer treated in the private health sector in Australia. Value-based healthcare is an essential change to how we deliver healthcare, shifting the focus from paying for individual services provided to a focus on the health outcomes gained over a full cycle of care. The Australian health system has unintentionally created barriers to value-based cancer care through fragmented care pathways and complex funding arrangements where patients can unexpectedly encounter high out-of-pocket costs. A team of clinicians, service providers, health systems and funding experts, private health insurers and consumers have collaborated to design and pilot a complete bundled package of care for breast cancer patients which aims to address these challenges. With 40 patients recruited to date, early evaluation results show positive patient experience of ‘joined-up’ care and financial transparency. This case study provides a high-level overview of the approach taken to design and implement the Breast Cancer Bundle and the lessons learned for its expansion in both public and private settings.

  • Open Access

    Diverse and vulnerable: experiences of private allied health practices managing through the coronavirus (COVID-19) pandemic. Implications for the financial viability of Australian primary care

    by M. John Petrozzi, Michael Wright, Rebekah Hoffman, Brendan Goodger, Sarah Wise

    Background: The majority of allied health services are delivered by small, private practices in the primary care setting with limited government funding. During the coronavirus disease 2019 (COVID-19) lockdowns these practices were subject to the same health orders as any other private business with only ‘essential services’ permitted to remain open. Research aim: We set out to understand the impact of the COVID-19 pandemic, and associated public health measures, on the financial viability of private allied health practices. Methods: Thirteen semi-structured interviews were conducted with primary care allied health practice owners and managers in Sydney. Data were analysed thematically. Findings: All of the interviewees reported experiencing the stress of balancing precarious finances caused by reduced and/or fluctuating patient demand. Patients’ reluctance to seek care was compounded by ambiguity around whether allied health services were ‘essential’. Manual therapies were particularly vulnerable to financial stress because their capacity to transition to telehealth and access to government funding were limited. Conversely, psychologists reported demand for their services exceeded what they could provide. Study implications: The findings are indicative of primary care allied health’s peripheral status in Australia’s primary care landscape. Greater priority to the funding and integration of primary care allied health is needed in primary care policy.


  • Open Access

    Managers' experiences of providing end‐of‐life care under the Home Care Package Program

    by Simone Simonetti, Deborah Parker, Holly A. Mack, Sarah Wise

    Objective: The study explored the experiences of Australian aged care providers in supporting clients on a home care package to die at home.Methods: Semistructured interviews were conducted with 13 aged care managers responsible for delivering services under the Home Care Package Program. Interviews were analysed thematically.Results: Four themes emerged that illuminated managers' experiences: struggling to meet a preference to die at home; lack of opportunities to build workforce capacity in end‐of‐life care; challenges in negotiating fragmented funding arrangements between health and aged care providers; and mixed success in collaborating across sectors.Conclusions: Aged care providers want to support older Australians who prefer to stay at home at the end of life. However, most clients are admitted to a residential facility when their care needs exceed a home care budget long before a specialist palliative care team will intervene. Budgets for health and aged care providers must be sufficient and flexible to support timely access to end‐of‐life care, to reward collaboration across sectors and to invest in building palliative care skills in the nursing and personal care workforce.